Cargando…

A role for IL-33–activated ILC2s in eosinophilic vasculitis

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but serious disease with poorly understood mechanisms. Here, we report that patients with EGPA have elevated levels of TSLP, IL-25, and soluble ST2, which are well-characterized cytokine “alarmins” that activate or modulate type 2 innate...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotas, Maya E., Dion, Jérémie, Van Dyken, Steven, Ricardo-Gonzalez, Roberto R., Danel, Claire J., Taillé, Camille, Mouthon, Luc, Locksley, Richard M., Terrier, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262498/
https://www.ncbi.nlm.nih.gov/pubmed/33974563
http://dx.doi.org/10.1172/jci.insight.143366
_version_ 1783719200959758336
author Kotas, Maya E.
Dion, Jérémie
Van Dyken, Steven
Ricardo-Gonzalez, Roberto R.
Danel, Claire J.
Taillé, Camille
Mouthon, Luc
Locksley, Richard M.
Terrier, Benjamin
author_facet Kotas, Maya E.
Dion, Jérémie
Van Dyken, Steven
Ricardo-Gonzalez, Roberto R.
Danel, Claire J.
Taillé, Camille
Mouthon, Luc
Locksley, Richard M.
Terrier, Benjamin
author_sort Kotas, Maya E.
collection PubMed
description Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but serious disease with poorly understood mechanisms. Here, we report that patients with EGPA have elevated levels of TSLP, IL-25, and soluble ST2, which are well-characterized cytokine “alarmins” that activate or modulate type 2 innate lymphoid cells (ILC2s). Patients with active EGPA have a concurrent reduction in circulating ILC2s, suggesting a role for ILC2s in the pathogenesis of this disease. To explore the mechanism of these findings in patients, we established a model of EGPA in which active vasculitis and pulmonary hemorrhage were induced by IL-33 administration in predisposed, hypereosinophilic mice. In this model, induction of pulmonary hemorrhage and vasculitis was dependent on ILC2s and signaling through IL4Rα. In the absence of IL4Rα or STAT6, IL-33–treated mice had less vascular leak and pulmonary edema, less endothelial activation, and reduced eotaxin production, cumulatively leading to a reduction of pathologic eosinophil migration into the lung parenchyma. These results offer a mouse model for use in future mechanistic studies of EGPA, and they suggest that IL-33, ILC2s, and IL4Rα signaling may be potential targets for further study and therapeutic targeting in patients with EGPA.
format Online
Article
Text
id pubmed-8262498
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-82624982021-07-13 A role for IL-33–activated ILC2s in eosinophilic vasculitis Kotas, Maya E. Dion, Jérémie Van Dyken, Steven Ricardo-Gonzalez, Roberto R. Danel, Claire J. Taillé, Camille Mouthon, Luc Locksley, Richard M. Terrier, Benjamin JCI Insight Research Article Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but serious disease with poorly understood mechanisms. Here, we report that patients with EGPA have elevated levels of TSLP, IL-25, and soluble ST2, which are well-characterized cytokine “alarmins” that activate or modulate type 2 innate lymphoid cells (ILC2s). Patients with active EGPA have a concurrent reduction in circulating ILC2s, suggesting a role for ILC2s in the pathogenesis of this disease. To explore the mechanism of these findings in patients, we established a model of EGPA in which active vasculitis and pulmonary hemorrhage were induced by IL-33 administration in predisposed, hypereosinophilic mice. In this model, induction of pulmonary hemorrhage and vasculitis was dependent on ILC2s and signaling through IL4Rα. In the absence of IL4Rα or STAT6, IL-33–treated mice had less vascular leak and pulmonary edema, less endothelial activation, and reduced eotaxin production, cumulatively leading to a reduction of pathologic eosinophil migration into the lung parenchyma. These results offer a mouse model for use in future mechanistic studies of EGPA, and they suggest that IL-33, ILC2s, and IL4Rα signaling may be potential targets for further study and therapeutic targeting in patients with EGPA. American Society for Clinical Investigation 2021-06-22 /pmc/articles/PMC8262498/ /pubmed/33974563 http://dx.doi.org/10.1172/jci.insight.143366 Text en © 2021 Kotas et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Kotas, Maya E.
Dion, Jérémie
Van Dyken, Steven
Ricardo-Gonzalez, Roberto R.
Danel, Claire J.
Taillé, Camille
Mouthon, Luc
Locksley, Richard M.
Terrier, Benjamin
A role for IL-33–activated ILC2s in eosinophilic vasculitis
title A role for IL-33–activated ILC2s in eosinophilic vasculitis
title_full A role for IL-33–activated ILC2s in eosinophilic vasculitis
title_fullStr A role for IL-33–activated ILC2s in eosinophilic vasculitis
title_full_unstemmed A role for IL-33–activated ILC2s in eosinophilic vasculitis
title_short A role for IL-33–activated ILC2s in eosinophilic vasculitis
title_sort role for il-33–activated ilc2s in eosinophilic vasculitis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262498/
https://www.ncbi.nlm.nih.gov/pubmed/33974563
http://dx.doi.org/10.1172/jci.insight.143366
work_keys_str_mv AT kotasmayae aroleforil33activatedilc2sineosinophilicvasculitis
AT dionjeremie aroleforil33activatedilc2sineosinophilicvasculitis
AT vandykensteven aroleforil33activatedilc2sineosinophilicvasculitis
AT ricardogonzalezrobertor aroleforil33activatedilc2sineosinophilicvasculitis
AT danelclairej aroleforil33activatedilc2sineosinophilicvasculitis
AT taillecamille aroleforil33activatedilc2sineosinophilicvasculitis
AT mouthonluc aroleforil33activatedilc2sineosinophilicvasculitis
AT locksleyrichardm aroleforil33activatedilc2sineosinophilicvasculitis
AT terrierbenjamin aroleforil33activatedilc2sineosinophilicvasculitis
AT kotasmayae roleforil33activatedilc2sineosinophilicvasculitis
AT dionjeremie roleforil33activatedilc2sineosinophilicvasculitis
AT vandykensteven roleforil33activatedilc2sineosinophilicvasculitis
AT ricardogonzalezrobertor roleforil33activatedilc2sineosinophilicvasculitis
AT danelclairej roleforil33activatedilc2sineosinophilicvasculitis
AT taillecamille roleforil33activatedilc2sineosinophilicvasculitis
AT mouthonluc roleforil33activatedilc2sineosinophilicvasculitis
AT locksleyrichardm roleforil33activatedilc2sineosinophilicvasculitis
AT terrierbenjamin roleforil33activatedilc2sineosinophilicvasculitis